A new clinical trial will be conducted based on the safety and efficacy of JointAlive® on the knee-joint function in adults with knee arthritis. The clinical trial has been officially approved by the Health Canada, and has registered on ClinicalTrial.gov, a resource provided by the U.S. National Library of Medicine.
Osteoarthritis (OA) is a joint degenerative disease caused by the wear and tear on joints over time. As a result, the protective cartilage of the bone in joints gradually wears away. Common symptoms of OA including joint pain, aching and stiffness. The lifetime risk of developing OA in the knee is 40% in men and 47% in women. It is estimated that approximately 19% of Americans aged 45 and older are affected by knee OA. Knee OA accounts for 83% of the global burden caused by all OA types. Pain and stiffness in knees, a large weight-bearing joint, often leads to disability, which interferes with daily life activities and demands expensive medical treatments or care.
Due to the limitations of current OA treatment methods, there is an increasing demand for effective and safer alternatives, such as natural health products with healthy functions supporting potential. The investigational product, JointAlive®, is a supplement designed to alleviate knee OA symptoms and improve knee functions. The study will focus on investigating the safety and efficacy of JointAlive® in reducing knee OA symptoms and improving joint functions in healthy adults with mild to moderate knee OA.
For more study details, please visit:
 Zhang, Y., & Jordan, J. (2010, August). Epidemiology of Osteoarthritis. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2920533